# STAT News

Type: Company

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/stat-news-company
Canonical HTML page: https://gethealthbrief.com/entity/stat-news-company

## Timeline

- **2027-Q1**: Expected FDA submission — Lilly plans to file retatrutide for FDA approval.
- **2026-08-19T20:15:00Z**: Hartford Courant reports Trump picks Overton — The Hartford Courant reports Trump picks Dr. Heidi Overton, a top White House aide, to lead the FDA.
- **2026-08-19T20:00:00Z**: ABC7 News reports Trump picks Overton — ABC7 News publishes a headline stating Trump picks Dr. Heidi Overton, a top White House aide, to lead the FDA.
- **2026-08-19T01:18:25Z**: STAT News reports Trump expected to pick Overton — STAT reports that President Trump is expected to choose White House adviser and physician Heidi Overton to lead the Food and Drug Administration.
- **2026-08-03**: Early access program announced — Lilly announced an expanded access program for retatrutide, allowing eligible patients to receive the drug before FDA approval.
- **2026-07-01**: 80-week trial results released — Lilly reported 22.6% average weight loss with highest retatrutide dose in adults with severe obesity and heart disease.

## Recent coverage (3 stories)

### Heidi Overton FDA pick: 3 regulatory areas health IT should watch
2026-08-19 21:12:01 · Sentiment: Neutral · Impact: 7/10 · Sources: 3

Reports that Dr. Heidi Overton will be nominated to lead FDA introduce new regulatory uncertainty for health IT vendors, medical device manufacturers, and digital health companies. As a White House adviser without a public FDA track record, her stance on software-as-a-medical-device, telehealth, and AI-enabled diagnostics is unclear. Health technology leaders should monitor confirmation and early policy signals.
Full story: https://gethealthbrief.com/story/overton-fda-health-it-regulatory-watch

### Eli Lilly’s retatrutide EAP: access for patients with 2+ severe comorbidities
2026-08-05 10:24:43 · Sentiment: Positive · Impact: 6/10 · Sources: 2

Eli Lilly opens an expanded access program for its triple-agonist retatrutide, offering a potential lifeline to patients with refractory obesity and multiple complications who cannot wait for FDA approval. The program highlights ongoing access gaps in obesity care and the need for real-world evidence.
Full story: https://gethealthbrief.com/story/eli-lilly-retatrutide-expanded-access-obesity-drug-2026

### Big Pharma Antibiotic Pipelines Nosedive 35% as Market Challenges Persist
2026-03-10 11:43:38 · Sentiment: Negative · Impact: 7/10 · Sources: 2

A new analysis reveals a 35% decline in antimicrobial R&D among the world's largest pharmaceutical companies over the last five years. This retreat highlights a deepening crisis in the antibiotic market, where low returns on investment are driving major players toward more lucrative therapeutic areas.
Full story: https://gethealthbrief.com/story/big-pharma-antibiotic-pipeline-decline-analysis

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.